4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Alopecia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 199 ongoing clinical trials involving Alopecia
Of the 199 trials,76 trials are in Phase II
Furthermore, 55 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Alopecia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Alopecia, a Dermatology Indication. Asia-Pacific boasts of the highest number of ongoing clinical trials involving Alopecia. North America and the Middle East and Africa are among some of the other prominent regions involved in Alopecia-related drug trials.

Pfizer Inc: The leading ongoing Alopecia-related clinical trials sponsor

Pfizer Inc, the United States of America-based pharmaceutical company, is the top sponsor for Alopecia-related ongoing clinical trials.

Concert Pharmaceuticals Inc, Isfahan University of Medical Sciences, King Chulalongkorn Memorial Hospital, Suzhou Zelgen Biopharmaceutical Co Ltd, and Memorial Sloan Kettering Cancer Center are a few other notable sponsors involving Alopecia.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Alopecia

Dutasteride (Avodart, Zagallo, Avolve, Duagen, Avidart, Duagene)Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone), and Betamethasone (Antebate)are among the key marketed drugs involving Alopecia.

Dutasteride (Avodart, Zagallo, Avolve, Duagen, Avidart, Duagene), a 3 Oxo 5 Alpha Steroid 4 Dehydrogenase 1 Inhibitor; 3 Oxo 5 Alpha Steroid 4 Dehydrogenase 2 Inhibitor, is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention (AUR), and reduce the risk of the need for BPH-related surgery. The drug is marketed globally including in the US, Australia, France, Germany, and Japan by GlaxoSmithKline Plc. Dutasteride was first approved in 2001 and as soft gelatin capsules for the oral route of administration.

Methylprednisolone (Depo-Medrate; Depo-Medrol; Depo-Medrone; Medrate), a Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist. The drug is marketed globally including in the US, Australia, France, Germany, and Japan by Pfizer Inc. Methylprednisolone was first approved in 1957 and formulated as tablets for oral administration, lyophilized powder for solution, suspension, and solution for intravenous, intramuscular, intraarticular, intralesional, intrasynovial route of administration.